Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Alligator Bioscience AB ( (SE:ATORX) ).
Alligator Bioscience announced a new investigator-initiated Phase 2/3 trial to evaluate the efficacy of mitazalimab in combination with FOLFOX chemotherapy for previously treated biliary tract cancer. This trial, led by Prof. Cindy Neuzillet and Dr. Matthieu Delaye, aims to address the unmet medical needs in this cancer type and could potentially improve patient outcomes. The study, sponsored by Unicancer and supported by the PRODIGE intergroup, will enroll 112 patients across 30 sites in France, with patient enrollment expected to begin in the second quarter of 2026. This initiative underscores the scientific interest in mitazalimab’s therapeutic potential beyond pancreatic cancer and highlights Alligator Bioscience’s commitment to advancing cancer treatment options.
More about Alligator Bioscience AB
Alligator Bioscience is a biotechnology company based in Lund, Sweden, specializing in the development of clinical-stage tumor-directed antibody drugs. The company focuses on the CD40 receptor, an immuno-oncology approach that enhances T cell priming and counteracts the immunosuppressive tumor microenvironment. Their lead drug candidate, mitazalimab, is advancing towards Phase 3 development and has shown promising results in metastatic pancreatic cancer.
YTD Price Performance: -80.05%
Average Trading Volume: 450,331
Technical Sentiment Signal: Sell
Current Market Cap: SEK146.2M
For an in-depth examination of ATORX stock, go to TipRanks’ Overview page.